EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, SNPHY: Santen Pharmaceutical Co. Ltd

21 Nov 2025
LAST:

10.29

CHANGE:
 0.24		OPEN:
10.29		HIGH:
10.29		ASK:
0.00		VOLUME:
800
CHG(%):
2.39		PREV:
10.05		LOW:
10.29		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
21 Nov 2510.2910.2910.2910.29800
20 Nov 2510.0510.229.6610.054.8K
19 Nov 2510.4410.449.9510.10149.6K
18 Nov 2510.0910.1810.0610.1891.7K
17 Nov 2510.2710.6810.2710.682.8K
14 Nov 2510.3110.3110.3110.31200
13 Nov 2510.0010.139.8110.081.3K
12 Nov 259.889.889.509.7313.8K
11 Nov 259.9410.059.949.941.2K
10 Nov 259.709.779.629.683.5K

PROFILE

Name:Santen Pharmaceutical Co. Ltd
About:Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prostaglandin F2a derivative filed for marketing approval for the treatment of glaucoma and ocular hypertension; and epinastine hydrochloride, a histamine H1 receptor antagonist filed for marketing approval to treat allergic conjunctivitis. The company also offers netarsudil mesylate/latanoprost, a fixed dose combination drug of a ROCK inhibitor and a prostaglandin F2a derivative which is in phase III clinical trial for the treatment of glaucoma and ocular hypertension; and sepetaprost, a prostaglandin analogue eye drop drug that is in phase III clinical trials for the treatment of glaucoma and ocular hypertension. In addition, it develops oxymetazoline hydrochloride, a direct-acting alpha adrenergic receptor agonist which is in phase III clinical trial for treatment of ptosis; and omidenepag isopropyl, an EP2 receptor agonist that is in phase III clinical trial for the treatment of glaucoma and ocular hypertension. Further, the company offers atropine sulfate, a non-selective muscarinic antagonist that is in phase II/III clinical trials for the treatment of juvenile myopia; olodaterol hydrochloride, a ß2 receptor agonist that has completed phase 1/2a clinical trial for the treatment of a dry eye; and sirolimus, an ophthalmic suspension which is in phase 2a clinical trial for the treatment of fuchs endothelial corneal dystrophy and meibomian gland dysfunction. The company was founded in 1890 and is headquartered in Osaka, Japan.
Sector:Healthcare
Address:Grand Front Osaka Tower A, Osaka, Japan, 530-8552
Website:https://www.santen.com/en
CUSIP:80287P100
ISIN:US80287P1003
FIGI:BBG0016504R1
LEI:529900TPT3I7C17MIM03

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:15.86 
Forward P/E:13.53 
Price to Sales:0.01 
Price to Book:2.03 
DivYield:0.02 
Div/Share:36.00 
Revenue:293.97B 
EBITDA:61.437B 
Shares:327.61M 
Market Cap:3.369B 

TECHNICAL INDICATORS

MA5:10.260.3%
MA10:10.101.8%
MA20:10.002.8%
MA50:10.401.1%
MA100:10.724.2%
MA200:10.421.3%
STO9:58.25
STO14:62.91
RSI14:58.53
WPR14:-37.09
MTM14:0.44
ROC14:0.04 
ATR:0.37 
Week High:10.683.8%
Week Low:9.666.5%
Month High:10.683.8%
Month Low:9.221.3%
Year High:12.7924.4%
Year Low:8.6518.9%
Volatility:3.06 

RECENT SPLITS

Date Ratio
02 Apr 20155-2